Elevance Health, Inc. (ELV)
NYSE · Indianapolis, Indiana, USA · Founded 1946 · CEO Gail Boudreaux
Valuation summary
$670.87 fair value versus $390.16 in the market, a difference of +72.0%. Rated Strong Buy.
| Fair value per share | $670.87 |
| Current share price | $390.16 |
| Upside / downside | +72.0% |
| Bear case | $257.97 |
| Bull case | $1,335.26 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.60% |
| Market capitalisation | $84B |
| EV / Sales | 0.5x |
About Elevance Health, Inc.
Traces to Blue Cross of Indiana, founded 1946, and became Anthem before renaming to Elevance in 2022. Gail Boudreaux has been CEO since 2017. Elevance is one of the largest US health insurers, holding Blue Cross Blue Shield licences across 14 states, and covers roughly 45 million members across commercial, Medicare and Medicaid plans. Carelon, its health services arm, is an attempt to follow UnitedHealth's Optum model of owning care delivery as well as insurance.
Investment case
- Blue Cross Blue Shield brand licences are effectively irreplaceable competitive positions in their states.
- Carelon diversifies away from pure insurance underwriting into higher-margin services.
- Scale advantages in negotiating provider rates are meaningful and compounding.
Key risks
- Medicaid redeterminations left a sicker member pool; management calls 2026 the trough year for Medicaid margins and is exiting the Washington, D.C. and Louisiana Medicaid markets.
- Medicare Advantage reimbursement rates have tightened and utilisation has run above expectations.
- Health insurance is politically exposed in a way few industries are.
Recent developments
- 2026-10-21 · Q3 adjusted EPS up 16% to $6.99 as the benefit expense ratio improves 70bp to 90.6%; 2026 adjusted EPS outlook raised to at least $29.00 source
Revenue by segment
| Commercial & Specialty | 43% |
| Government Business | 45% |
| Carelon Services | 12% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $207.7B | $7.8B |
| Year 2 | $215.1B | $8.6B |
| Year 3 | $222.9B | $9.4B |
| Year 4 | $230.9B | $10.3B |
| Year 5 | $239.2B | $11.3B |
What the street says
Trades at a discount to UnitedHealth, which most attribute to Carelon being less developed than Optum. In September 2026 management reaffirmed 2026 adjusted EPS of at least $27, said third-quarter results were tracking ahead of plan and targeted at least 12% EPS growth in 2027.
Comparable companies: CI · COR · CVS · UNH · MDLN · TEVA · HCA · GEHC
Open the interactive model, price chart and sensitivity grid →